Cytokine production after the addition of sCD40L
| Treatment . | Cytokines, pg/mL . | ||||||
|---|---|---|---|---|---|---|---|
| IL-10 . | IL-6 . | IL-8 . | TGF-β . | IL-2 . | GM-CSF . | TNF-α . | |
| 1. sCD40L− | 25 ± 15 | 466 ± 323 | 1852 ± 683 | 2013 ± 551 | 653 ± 37 | 62 ± 10 | 120 ± 80 |
| 2. sCD40L+ | 24 ± 7 | 445 ± 252 | 1063 ± 188 | 2426 ± 552 | 633 ± 56 | 61 ± 22 | 125 ± 63 |
| 3. sCD40L− + anti-CD3/28 | 530 ± 123 | 494 ± 123 | 506 ± 85 | 2624 ± 717 | 15 000 ± 3134 | 1298 ± 209 | 12 236 ± 1192 |
| 4. sCD40L+ + anti-CD3/28 | 792 ± 143*† | 651 ± 149*‡ | 427 ± 52 | 2430 ± 672 | 20 004 ± 3879 | 1955 ± 375 | 17 031 ± 1738 |
| Treatment . | Cytokines, pg/mL . | ||||||
|---|---|---|---|---|---|---|---|
| IL-10 . | IL-6 . | IL-8 . | TGF-β . | IL-2 . | GM-CSF . | TNF-α . | |
| 1. sCD40L− | 25 ± 15 | 466 ± 323 | 1852 ± 683 | 2013 ± 551 | 653 ± 37 | 62 ± 10 | 120 ± 80 |
| 2. sCD40L+ | 24 ± 7 | 445 ± 252 | 1063 ± 188 | 2426 ± 552 | 633 ± 56 | 61 ± 22 | 125 ± 63 |
| 3. sCD40L− + anti-CD3/28 | 530 ± 123 | 494 ± 123 | 506 ± 85 | 2624 ± 717 | 15 000 ± 3134 | 1298 ± 209 | 12 236 ± 1192 |
| 4. sCD40L+ + anti-CD3/28 | 792 ± 143*† | 651 ± 149*‡ | 427 ± 52 | 2430 ± 672 | 20 004 ± 3879 | 1955 ± 375 | 17 031 ± 1738 |
Six PBMC samples (106/mL) from metastatic prostate cancer patients were incubated in X-VIVO15 medium with (2 μg/mL) or without sCD40L, as well as ± anti-CD3/28 beads. Three days later, the supernatant was harvested for cytokine analysis. Results represent a mean of 6 samples ± SE. Parametric t test was analyzed either between treatments 1 and 2 or between treatments 3 and 4.
Statistical difference.
P < .01.
P < .05.